Teva Rasagiline Filing Set For Second Half 2003; Firm Touts Metabolic Profile
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva will likely emphasize the once-daily dosing and metabolic profile of its MAO-B inhibitor rasagiline to distinguish the Parkinson’s disease therapy from selegiline.